Lessons from trials in hypertensive type 2 diabetic patients

Current Hypertension Reports

Volumn 5, Issue 4, 2003, Pages 322-328

  Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; ANGIOTENSIN RECEPTOR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG CLASSIFICATION; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; HEART DEATH; HUMAN; HYPERTENSION; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; CONTROLLED CLINICAL TRIAL; DIABETIC ANGIOPATHY; DRUG ANTAGONISM; DRUG EFFECT; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN;

EID: 0642376308     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0041-x     Document Type: Review

References (58)

1. The National High Blood Pressure Education Program Working Group: National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994, 23:145-158.
2. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?. J Hypertens 2002, 20:2099-2110.
3. Curb JD, Pressel SL, Cutler JA, et al.: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276:1886-1892.
4. Tuomilehto J, Rastenyte D, Birkenhäger WH, et al.: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999, 340:677-684.
5. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755-1762.
6. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086-1097.
7. Vasan RS, Larson MG, Leip EP, et al.: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001, 345:1291-1297.
8. Shulman NB, Ford CE, Hall WD, et al.: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989, 13:I80-I93.
9. Voyaki SM, Staessen JA, Thijs L, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001, 19:511-519.
10. Heart Outcomes Prevention Evaluation (HOPE) Study investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-259.
11. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
12. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
13. Parving HH, Lehnert H, Bröchner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
14. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes. UKPDS38. BMJ 1998, 317:703-713.
15. Estacio RO, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645-652.
16. PROGRESS Collaborative Study Group: Randomised trial of perindopril-based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041.
17. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153.
18. Mancia G, Grassi G: Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002, 20:1461-1464.
19. Mancia G, Brown M, Castaigne A, et al.: Outcome with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003, 41:431-436.
20. Hansson L, Hedner T, Lund-Johansen P, et al.: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365.
21. Lindholm LH, Hansson L, Ekbom T, et al.: Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000, 18:1671-1675.
22. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
23. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complication in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713-720.
24. Niskanen L, Hedner T, Hansson L, et al.: Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001, 24:2091-2096.
25. Lindholm LH, Ibsen H, Dahlöf B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010.
26. Bakris GL, Williams M, Dworkin L, et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000, 36:646-661.
27. Ruilope LM, Campo C, Rodicio JL: Blood pressure control, proteinuria and renal outcome in chronic renal failure. Curr Opin Nephrol Hypertens 1998, 7:145-148.
28. Ruilope LM, Schiffrin E: Blood pressure control and benefits of antihypertensive therapy: does it make a difference what agent we use? Hypertension 2001, 38:537-542.
29. The PROCOPA Study Group: Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. J Hypertens 2002, 20:729-737.
30. Ruilope LM, Salvetti A, Jamerson K, et al.: Renal function and intensive lowering of blood pressure in the hypertensive subjects of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001, 12:218-225.
31. Voyaki SM, Staessen JA, Thijs L, et al.: Follow-up of renal function intreated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens 2001, 19:511-519.
32. Mann JFE, Gerstein HC, Pogue J, et al.: Renal insufficiency as predictor of cardiovascular outcomes and impact of ramipril: the HOPE randomization trial. Ann Intern Med 2001, 134:629-636.
33. Ravid M, Lang R, Rachmani R, Lischner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996, 156:286-289.
34. Chan JC, Cockram CM, Nicholls MG, et al.: Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ 1992, 305:98-105.
35. Lacourciere Y, Nadeau A, Poirier L, Tancrede G: Captopril or conventional therapy in hypertensive type II diabetics. Three year analysis. Hypertension 1993, 21:786-794.
36. Sano T, Kawamura T, Matsumae H, et al.: Effects of long-term enalapril treatment on persistent microalbuminuria in well controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994, 17:420-424.
37. Lebovitz HE, Wiegmann TB, Cnaan A, et al.: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline microalbuminuria. Kidney Int 1994, 45(Suppl):S150-S155.
38. Bakris GL, Copley JB, Vicknair N, et al.: Calcium Channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996, 50:1641-1650.
39. Agardh CD, Garcia Puig J, Charbonnel B, et al.: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996, 10:185-192.
40. Melbourne Diabetic Nephropathy Study Group: Comparison between perindopril and nifedipine in normotensive patients with incipient diabetic nephropathy. BMJ 1991, 302:210-216.
41. Velussi M, Brocco E, Frigato E et al.: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996, 45:216-222.
42. Ruggenenti P, Mosconi L, Bianchi L, et al.: Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients. Am J Kidney Dis 1994, 24:753-761.
43. Ravid M, Brosch D, Levi Z, et al.: Use of enalapril to attenuate decline in renal function in normotensive normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Ann Intern Med 1998, 128:982-988.
44. Parving HH, Hovind P, Rossing K, et al.: Evolving strategies for renoprotection: diabetic nephropathy. Curr Opin Nephrol Hypertens 2001, 10:515-522.
45. Chalmers JP: Ongoing trials of angiotensin-converting enzyme inhibition: what they can tell us. Am J Hypertens 2001, 14:270S-275S.
46. Weber M: Angiotensin II receptor blockers and cardiovascular outcomes: the evidence now and in the future. J Renin Agiontensin Aldosterone Syst 2001, 2(Suppl 2):S12-S16.
47. Mogensen CE, Neldam S, Tikkanen I, et al., for the CALM study group: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440-1444.
48. Laverman GD, Navis G, Henning RH, et al.: Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002, 62:1020-1025.
49. Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117-124.
50. Lindholm LH, Ibsen H, Borch-Jonsen K, et al.: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in in hypertension study. J Hypertens 2002, 20:1879-1886.
51. Alderman MH, Cohen H, Madhavan S: Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999, 33:1130-1134.
52. Savage PJ, Pressel SL, Curb JD, et al.: influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. Arch Intern Med 1998, 158:741-751.
53. Velussi M, Brocco E, Frigato F, et al.: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996, 45:216-222.
54. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
55. Dahlöf B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
56. Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-912.
57. Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF: Renal function: the cinderella of cardiovascular risk profile. J Am Coll Cardiol 2001, 38:1782-1787.
58. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.